1043. Deputy Michael Fitzmaurice asked the Minister for Health if urgent approval can be granted for the medicines nivolumab (opdivo) and chemotherapy, authorised by the European Medicines Agency (EMA) since October 2021 for gastric cancer with a PD less than 1 and CPS of 7.5, and pembrolizumab, authorised since December 2023 by the EMA for gastric cancer with a PD less than 1 and CPS greater than or equal to 1, as currently, neither the HSE nor the NCCP have included these drugs for the treatment of cancer on their reimbursement scheme for a person (details supplied), though both his surgeon and oncologists have strongly recommended immunotherapy as the best and most viable course of treatment for him; and if he will make a statement on the matter. [44066/24]

Summary

1043. Deputy Michael Fitzmaurice asked the Minister for Health if urgent approval can be granted for the medicines nivolumab (opdivo) and chemotherapy, authorised by the European Medicines Agency (EMA) since October 2021 for gastric cancer with a PD less than 1 and CPS of 7.5, and pembrolizumab, authorised since December 2023 by the EMA for gastric cancer with a PD less than 1 and CPS greater than or equal to 1, as currently, neither the HSE nor the NCCP have included these drugs for the treatment of cancer on their reimbursement scheme for a person (details supplied), though both his surgeon and oncologists have strongly recommended immunotherapy as the best and most viable course of treatment for him; and if he will make a statement on the matter. [44066/24]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 5 November 2024

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.